Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era
โ Scribed by Alonzo, T A; Wells, R J; Woods, W G; Lange, B; Gerbing, R B; Buxton, A B; Neudorf, S; Sanders, J; Smith, F O; Feig, S A
- Book ID
- 110056285
- Publisher
- Nature Publishing Group
- Year
- 2005
- Tongue
- English
- Weight
- 131 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0887-6924
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The Childrens Cancer Study Group conducted four therapeutic studies on a total of 1006 children with acute nonlymphocytic leukemia from 1972 to 1983. This report describes the therapeutic strategies of these studies and examines trends in induction rates and long-term outcome over this period. The r
Amsacrine (AMSA) and cyclocytidine were studied as retrieval therapy in 122 pediatric patients with acute nonlymphoblastic leukemia (ANLL). Patients either failed to achieve sustained initial remissions or were in relapse. Induction therapy consisted of intravenous (IV) AMSA (75 mg/mz) from days 1 t
Problem. Therapy of children with relapsed acute lymphoblastic leukemia (ALL) not achieving a second remission (CR2) after an initial reinduction attempt is problematic. Methods. 52 children with ALL in first relapse received high-dose cytosine arabinoside and L-asparaginase (HDAraC/L-Asp) after fa